Rapport Therapeutics, Inc. Common Stock
Symbol: RAPP (NASDAQ)
29.84
▲ (6.67%) 1.865
Company Description:
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
Key Stats
- Today's Open: $27.97
- Today's High: $30.645
- Today's Low: $26.22
- Today's Volume: 819.80K
- Yesterday Close: $27.97
- Yesterday High: $28.43
- Yesterday Low: $26.33
- Yesterday Volume: 837.36K
- Last Min Volume: 2
- Last Min High: $29.835
- Last Min Low: $29.835
- Last Min VWAP: $29.835
Company Profile
- Name: Rapport Therapeutics, Inc. Common Stock
- Website: https://www.rapportrx.com
- Listed Date: 2024-06-07
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0002012593
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $1.29B
- Round Lot: 100
- Outstanding Shares: 46.11M
- Asset Type: CS
RECENT FILINGS FOR RAPP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-19 | 4 | View |
| 2025-09-18 | SCHEDULE 13D/A | View |
| 2025-09-17 | 144 | View |
| 2025-09-17 | 144 | View |
| 2025-09-17 | 4 | View |
| 2025-09-15 | 4 | View |
| 2025-09-15 | 4 | View |
| 2025-09-11 | 4 | View |
| 2025-09-10 | 8-K | View |
| 2025-09-10 | 424B5 | View |
| 2025-09-10 | 4 | View |
| 2025-09-08 | 424B5 | View |
| 2025-09-08 | 144 | View |
| 2025-09-08 | 8-K | View |
| 2025-09-08 | 8-K | View |
| 2025-08-18 | 4 | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-07-16 | 4 | View |
| 2025-07-09 | EFFECT | View |
Latest News on RAPP